Seer, Inc.: directors' dealings · United States · SEC (Form 4)

About Seer, Inc.

Seer, Inc. is a U.S.-based life sciences company listed on the NASDAQ in the United States. For French-speaking investors in France, Belgium, and Switzerland, it is best viewed as a proteomics and biotechnology infrastructure story rather than a traditional therapeutics company. Seer’s core mission is to enable deep, unbiased protein analysis in order to improve understanding of human biology and, ultimately, support research that may lead to better health outcomes. The company was founded in 2017 and was incorporated in Delaware under the name Seer Biosciences, Inc. before adopting the Seer, Inc. name in 2018. Its headquarters and main R&D operations are in Redwood City, California, placing it squarely in the Bay Area biotech ecosystem. Seer’s business model centers on commercializing research-use-only proteomics tools. Its flagship offering is the Proteograph Product Suite, an integrated platform that combines engineered nanoparticles, consumables, automation instruments, and data-analysis software. The platform is designed to expand the depth and consistency of proteomic workflows, making high-throughput protein analysis more accessible to academic laboratories, biopharma companies, contract research organizations, and other research institutions. In practical terms, Seer is attempting to build a differentiated technology platform in a still-developing market where adoption depends on scientific validation, workflow compatibility, and reproducible data quality. From a competitive standpoint, Seer operates in a specialized segment of the life sciences tools market where barriers to entry include intellectual property, instrument integration, and customer trust. The company positions its technology around deeper proteomic coverage, reproducibility, and workflow standardization. Its international footprint extends beyond the United States into Europe and other regions through a customer and partner base that includes research organizations and commercial life-science users. Seer also supports customer engagement through a Technology Access Center model, including facilities in Redwood City and Bonn, Germany, which help demonstrate the platform and support user adoption. Recent developments underline that Seer remains in an execution phase. In February 2026, the company reported full-year 2025 results showing revenue of approximately $16.6 million and provided 2026 revenue guidance in the $16 million to $18 million range, reinforcing the view that the business is still at an early commercialization stage. The company has also continued to expand its product suite, including higher-throughput iterations of the Proteograph platform, reflecting a strategy focused on broadening use cases and improving scalability. For equity investors, that means SEER remains a high-risk, innovation-driven NASDAQ name where adoption momentum, product differentiation, and cash discipline are likely to matter more than near-term profitability. SEC Form 4 insider transactions should therefore be interpreted as one data point within a broader narrative of commercialization progress and strategic uncertainty.